Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorMonteagudo, Mònica
dc.contributor.authorRoset, Montse
dc.contributor.authorRodriguez-Blanco, Teresa
dc.contributor.authorMuñoz, Laura
dc.contributor.authorMiravitlles Fernández, Marc
dc.date.accessioned2021-04-22T08:03:28Z
dc.date.available2021-04-22T08:03:28Z
dc.date.issued2017-04-12
dc.identifier.citationMonteagudo M, Roset M, Rodriguez-Blanco T, Muñoz L, Miravitlles M. Characteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study. Int J Chron Obstruct Pulmon Dis. 2017 Apr 12;Volume 12:1145–1152.
dc.identifier.issn1178-2005
dc.identifier.urihttp://hdl.handle.net/11351/5895
dc.descriptionCOPD; Primary care; Treatment
dc.description.abstractObjective: To describe and compare demographic and clinical profile of patients newly initiated on aclidinium (ACL) or tiotropium (TIO) and identify factors associated with newly initiated ACL in real-life clinical practice during 2013 in Catalonia. Design: We performed a population-based, retrospective, observational study with data obtained from the Information System for Research Development in Primary Care, a population database that contains information of 5.8 million inhabitants (more than 80% of the Catalan population). Patients over 40 years old, with a recorded diagnosis of COPD and newly initiated treatment with either ACL or TIO during the study period (January to December 2013), were selected. A descriptive analysis of demographic and clinical characteristics was performed, and treatment adherence was also assessed for both cohorts. Results: A total of 8,863 individuals were identified, 4,293 initiated with ACL and 4,570 with TIO. They had a mean age of 69.4 years (standard deviation: 11.3), a median COPD duration of 3 years (interquartile range: 0–8), and 71% were males. Patients treated with ACL were older, with more respiratory comorbidities, a longer time since COPD diagnosis, worse forced expiratory volume in 1 second (% predicted), and with a higher rate of exacerbations during the previous year compared with TIO. It was found that 41.3% of patients with ACL and 62.3% of patients with TIO had no previous COPD treatment. Inhaled corticosteroid and long-acting β2-agonist were the most frequent concomitant medications (32.9% and 32.6%, respectively). Approximately 75% of patients were persistent with ACL or TIO at 3 months from the beginning of treatment, and more than 50% of patients remained persistent at 9 months. Conclusion: Patients initiated with ACL had more severe COPD and were taking more concomitant respiratory medications than patients initiated with TIO. ACL was more frequently initiated as part of triple therapy, while TIO was more frequently initiated as monotherapy.
dc.language.isoeng
dc.publisherDove Medical Press
dc.relation.ispartofseriesInternational Journal of Chronic Obstructive Pulmonary Disease;12
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPulmons - Malalties obstructives
dc.subjectAtenció primària - Catalunya
dc.subject.meshPulmonary Disease, Chronic Obstructive
dc.subject.mesh/drug therapy
dc.subject.meshPrimary Health Care
dc.subject.meshSpain
dc.titleCharacteristics of COPD patients initiating treatment with aclidinium or tiotropium in primary care in Catalonia: a population-based study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2147/COPD.S131016
dc.subject.decsenfermedad pulmonar obstructiva crónica
dc.subject.decs/farmacoterapia
dc.subject.decsatención primaria de la salud
dc.subject.decsEspaña
dc.relation.publishversionhttps://www.dovepress.com/characteristics-of-copd-patients-initiating-treatment-with-aclidinium--peer-reviewed-article-COPD
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Monteagudo M, Rodriguez-Blanco T] Primary Care University Research Institute Jordi Gol (IDIAP Jordi Gol), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Roset M] IMS Health, Barcelona, Spain. [Muñoz L] Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS), Barcelona, Spain. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. CIBER de Enfermedades Respiratorias (CIBERES), Barcelona, Spain.
dc.identifier.pmid28442901
dc.identifier.wos000399291200002
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record